Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced prostate cancer: early trial of JSB462 begins

NCT ID NCT07174063

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 30 times

Summary

This early-stage study tests a new drug called JSB462 in 15 Japanese men whose prostate cancer has spread to other parts of the body and hasn't responded to standard treatments. The main goal is to check the drug's safety and how the body processes it. This is not a cure but aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER (MCRPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Nagoya, Aichi-ken, 4668560, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo Ku, Tokyo, 1138677, Japan

  • Novartis Investigative Site

    RECRUITING

    Koto Ku, Tokyo, 1358550, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Kobe, 650-0017, Japan

Conditions

Explore the condition pages connected to this study.

METASTATIC PROSTATE CANCER (MCRPC)